期刊
RESPIRATORY RESEARCH
卷 18, 期 -, 页码 -出版社
BIOMED CENTRAL LTD
DOI: 10.1186/s12931-017-0559-0
关键词
Eosinophils; COPD; Asthma COPD overlap; ACOS
资金
- Almirall
- AstraZeneca
- Boehringer Ingelheim
- Chiesi
- Genentech
- GlaxoSmithKline
- Glenmark
- Merck
- NAPP
- Novartis
- Pfizer
- Skyepharma
- Takeda
- Teva
- Therevance
- Verona
Eosinophilic COPD appears to be a distinct patient subgroup with an increased corticosteroid response. Eosinophilic COPD has been labelled as part of the asthma COPD overlap syndrome (ACOS). We compared the clinical characteristics of eosinophilic COPD patients (without any clinical history of asthma) and COPD patients with a childhood history of asthma. COPD patients with asthma were characterised by more allergies and more exacerbations, but less eosinophilic inflammation. While terms such as ACOS are used to lump patients together, we report distinct differences between eosinophilic COPD and COPD patients with asthma, and propose that these groups should be split rather than lumped.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据